Trend Following
(11)
▼
Momentum
(6)
▼
Volatility
(5)
▼
Pattern Recognition
(5)
▼
Mean Reversion
(4)
▼
Volume Based
(5)
▼
Advanced
(10)
▼
BIOA
$22.1155
$
BioAge Labs, Inc. is a clinical-stage biopharmaceutical company that develops therapeutic product candidates for metabolic diseases. The company's technology platform and differentiated human datasets allows users to identify targets based on insights into molecular changes that drive aging. Its product includes azelaprag, an orally available small molecule that is in phase 1 clinical trial for the treatment of obesity; and initiated phase 2 clinical trial of azelaprag in combination with tirzepatide for the treatment of obesity in older adults. It also develops BGE-100, an orally available small molecule brain-penetrant NLRP3 antagonist for the treatment of diseases driven by neuroinflammation. The company was incorporated in 2015 and is based in Richmond, California.
Next Earnings
2026-02-25
Beta
1.4469382
Average Volume
Market Cap
Last Dividend
CIK
0001709941
ISIN
US09077V1008
CUSIP
09077V100
CEO
Kristen Fortney
Sector
Healthcare
Industry
Biotechnology
Full Time Employees
62
IPO Date
2024-09-26
Status
Active
Latest News
| Title | Headline | Publisher | Date |
|---|---|---|---|
| BioAge Announces Pricing of Upsized $115.0 Million Public Offering | EMERYVILLE, Calif., Jan. 21, 2026 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (Nasdaq: BIOA) ("BioAge", “the Company”), a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging, today announced the pricing of its upsized underwritten public offering of 5,897,435 shares of its common stock at a price to the public of $19.50 per share. The gross proceeds from this offering are expected to be approximately $115.0 million, before deducting underwriting discounts and commissions and other offering expenses payable by BioAge. The offering is expected to close on or about January 23, 2026, subject to the satisfaction of customary closing conditions. In addition, BioAge has granted the underwriters a 30-day option to purchase up to an additional 884,615 shares of common stock in connection with the offering. All of the shares of common stock are being offered by BioAge. | GlobeNewsWire | 2026-01-21 22:30:00 |
| BioAge Announces Proposed Public Offering | EMERYVILLE, Calif., Jan. 20, 2026 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (Nasdaq: BIOA) (“BioAge”, “the Company”), a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging, today announced a proposed underwritten public offering in which it intends to offer and sell, subject to market and other conditions, up to $75.0 million of shares of its common stock. | GlobeNewsWire | 2026-01-20 16:01:00 |
| BioAge Announces Indication Expansion for Oral NLRP3 Inhibitor BGE-102, with Plans to Initiate Phase 1b/2a Proof-of-Concept Clinical Trial in Patients with Diabetic Macular Edema in Mid-2026 | BGE-102 has the potential for therapeutic retinal exposure with oral delivery, reducing treatment burden in ocular indications currently treated with intravitreal therapies | GlobeNewsWire | 2026-01-20 09:00:00 |
| BioAge Rockets As It Takes On Eli Lilly's Takeover Play, Ventyx Bio | BioAge shares catapulted Monday on promising results for the company's cardiovascular diseases treatment, which could eventually rival Eli Lilly. | Investors Business Daily | 2026-01-12 13:05:01 |
| BioAge Announces Additional Positive Interim Phase 1 Data for BGE-102, a Novel Brain-Penetrant NLRP3 Inhibitor, Demonstrating Potential for Best-in-Class hsCRP Reduction in Participants with Elevated Cardiovascular Risk | First BGE-102 MAD cohort completed in obese individuals with elevated hsCRP receiving 120 mg QD; demonstrated rapid and profound reduction in inflammatory markers | GlobeNewsWire | 2026-01-12 09:00:00 |
| 2 Reasons I Wouldn't Touch BioAge Labs Stock With a 10-Foot Pole | BioAge Labs' leading candidate is far too early in the process to make reliable predictions. The biotech will encounter plenty of challengers in its chosen therapeutic area. | The Motley Fool | 2025-12-13 10:15:00 |
| BioAge Announces Positive Interim Phase 1 Data for BGE-102, a Novel Brain-Penetrant NLRP3 Inhibitor | BGE-102 was well-tolerated in SAD and initial MAD cohorts, with a pharmacokinetic profile supporting once-daily oral dosing Strong target engagement: BGE-102 achieved 90-98% suppression of IL-1β, a cytokine directly downstream of NLRP3, at Day 14 High brain penetration: BGE-102 doses of 60 mg and higher exceeded target IC90 levels in cerebrospinal fluid (CSF) at Day 14 Company is expanding the Phase 1 trial to include MAD cohorts in participants with obesity and elevated hsCRP, with data anticipated in first half of 2026 EMERYVILLE, Calif., Dec. 04, 2025 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (Nasdaq: BIOA) ("BioAge"), a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging, today announced positive interim data from the ongoing Phase 1 single ascending dose (SAD) / multiple ascending dose (MAD) clinical trial evaluating BGE-102, a potent, structurally novel, orally available, brain-penetrant small molecule NLRP3 inhibitor being developed for treatment of patients with cardiovascular risk factors. | GlobeNewsWire | 2025-12-04 09:00:00 |
| BioAge Labs to Present at Piper Sandler 37th Annual Healthcare Conference | EMERYVILLE, Calif., Nov. 25, 2025 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (NASDAQ: BIOA) ("BioAge", "the Company"), a clinical-stage biotechnology company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging, today announced that the Company will present at the Piper Sandler 37th Annual Healthcare Conference taking place in New York, NY on December 2-4, 2025. | GlobeNewsWire | 2025-11-25 16:30:00 |
SEC Filings
| Type | Filing Date | Accepted Date | Link |
|---|---|---|---|
| 4 | 2026-02-19 | 2026-02-19 | View Filing |
| 4 | 2026-02-19 | 2026-02-19 | View Filing |
| 4 | 2026-02-19 | 2026-02-19 | View Filing |
| 4 | 2026-02-19 | 2026-02-19 | View Filing |
| 4 | 2026-02-19 | 2026-02-19 | View Filing |
| SC 13G/A | 2026-02-17 | 2026-02-17 | View Filing |
| SC 13G/A | 2026-02-17 | 2026-02-17 | View Filing |
| SC 13G/A | 2026-02-13 | 2026-02-13 | View Filing |
| 4 | 2026-02-03 | 2026-02-03 | View Filing |
| 4 | 2026-02-03 | 2026-02-03 | View Filing |
| 8-K | 2026-01-22 | 2026-01-22 | View Filing |
| 424B5 | 2026-01-22 | 2026-01-22 | View Filing |
| 4 | 2026-01-21 | 2026-01-21 | View Filing |
| 424B5 | 2026-01-20 | 2026-01-20 | View Filing |
| 8-K | 2026-01-20 | 2026-01-20 | View Filing |
| 4 | 2026-01-15 | 2026-01-15 | View Filing |
| 4 | 2026-01-15 | 2026-01-15 | View Filing |
| 8-K | 2026-01-12 | 2026-01-12 | View Filing |
| 4 | 2026-01-06 | 2026-01-06 | View Filing |
| 4 | 2025-12-11 | 2025-12-11 | View Filing |
| 4 | 2025-12-05 | 2025-12-05 | View Filing |
| 8-K | 2025-12-04 | 2025-12-04 | View Filing |
| 10-Q | 2025-11-06 | 2025-11-06 | View Filing |
| 8-K | 2025-11-06 | 2025-11-06 | View Filing |
| S-3/A | 2025-11-05 | 2025-11-05 | View Filing |
| S-3/A | 2025-11-05 | 2025-11-05 | View Filing |
| S-3 | 2025-10-02 | 2025-10-02 | View Filing |
| S-3 | 2025-10-02 | 2025-10-02 | View Filing |
| SC 13G | 2025-08-14 | 2025-08-14 | View Filing |
| SC 13G/A | 2025-08-14 | 2025-08-14 | View Filing |
| 4 | 2025-08-11 | 2025-08-11 | View Filing |
| 10-Q | 2025-08-06 | 2025-08-06 | View Filing |
| 8-K | 2025-08-06 | 2025-08-06 | View Filing |
| 4 | 2025-06-09 | 2025-06-09 | View Filing |
| 4 | 2025-06-09 | 2025-06-09 | View Filing |
| 4 | 2025-06-09 | 2025-06-09 | View Filing |
| 4 | 2025-06-09 | 2025-06-09 | View Filing |
| 4 | 2025-06-09 | 2025-06-09 | View Filing |
| 8-K | 2025-06-09 | 2025-06-09 | View Filing |
| 8-K | 2025-06-04 | 2025-06-04 | View Filing |
| 10-Q | 2025-05-06 | 2025-05-06 | View Filing |
| 8-K | 2025-05-06 | 2025-05-06 | View Filing |
| ARS | 2025-04-17 | 2025-04-17 | View Filing |
| DEFA14A | 2025-04-17 | 2025-04-17 | View Filing |
| DEF 14A | 2025-04-17 | 2025-04-17 | View Filing |
| S-8 | 2025-03-20 | 2025-03-20 | View Filing |
| 10-K | 2025-03-20 | 2025-03-20 | View Filing |
| 8-K | 2025-03-20 | 2025-03-20 | View Filing |
| 4/A | 2025-03-10 | 2025-03-10 | View Filing |
| 4 | 2025-03-10 | 2025-03-10 | View Filing |
| 4/A | 2025-02-25 | 2025-02-25 | View Filing |
| 4 | 2025-02-20 | 2025-02-20 | View Filing |
| 4 | 2025-02-20 | 2025-02-20 | View Filing |
| 4 | 2025-02-20 | 2025-02-20 | View Filing |
| 4 | 2025-02-20 | 2025-02-20 | View Filing |
| 4 | 2025-02-20 | 2025-02-20 | View Filing |
| SC 13G/A | 2025-02-14 | 2025-02-14 | View Filing |
| SC 13G | 2025-02-14 | 2025-02-14 | View Filing |
| 4 | 2024-12-20 | 2024-12-20 | View Filing |
| SC 13G | 2024-11-14 | 2024-11-14 | View Filing |
| SC 13G | 2024-11-12 | 2024-11-12 | View Filing |
| 10-Q | 2024-11-07 | 2024-11-07 | View Filing |
| 8-K | 2024-11-07 | 2024-11-07 | View Filing |
| SC 13G | 2024-10-07 | 2024-10-07 | View Filing |
| SC 13D | 2024-10-04 | 2024-10-04 | View Filing |
| 4 | 2024-10-03 | 2024-10-03 | View Filing |
| 4 | 2024-10-01 | 2024-10-01 | View Filing |
| SC 13D | 2024-09-30 | 2024-09-30 | View Filing |
| 4 | 2024-09-27 | 2024-09-27 | View Filing |
| 4 | 2024-09-27 | 2024-09-27 | View Filing |
| 4 | 2024-09-27 | 2024-09-27 | View Filing |
| 4 | 2024-09-27 | 2024-09-27 | View Filing |
| 4 | 2024-09-27 | 2024-09-27 | View Filing |
| 4 | 2024-09-27 | 2024-09-27 | View Filing |
| SEC STAFF LETTER | 2024-09-25 | 2024-09-27 | View Filing |
| 4 | 2024-09-27 | 2024-09-27 | View Filing |
| 4 | 2024-09-27 | 2024-09-27 | View Filing |
| 8-K | 2024-09-27 | 2024-09-27 | View Filing |
| S-8 | 2024-09-26 | 2024-09-26 | View Filing |
| 424B4 | 2024-09-26 | 2024-09-26 | View Filing |
| EFFECT | 2024-09-26 | 2024-09-26 | View Filing |
| 3 | 2024-09-25 | 2024-09-25 | View Filing |
| S-1MEF | 2024-09-25 | 2024-09-25 | View Filing |
| 3 | 2024-09-25 | 2024-09-25 | View Filing |
| 3 | 2024-09-25 | 2024-09-25 | View Filing |
| 3 | 2024-09-25 | 2024-09-25 | View Filing |
| 3 | 2024-09-25 | 2024-09-25 | View Filing |
| 3 | 2024-09-25 | 2024-09-25 | View Filing |
| 3 | 2024-09-25 | 2024-09-25 | View Filing |
| 3 | 2024-09-25 | 2024-09-25 | View Filing |
| 3 | 2024-09-25 | 2024-09-25 | View Filing |
| 3 | 2024-09-25 | 2024-09-25 | View Filing |
| 3 | 2024-09-25 | 2024-09-25 | View Filing |
| 3 | 2024-09-25 | 2024-09-25 | View Filing |
| CERT | 2024-09-25 | 2024-09-25 | View Filing |
| CORRESP | 2024-09-25 | 2024-09-25 | View Filing |
| S-1/A | 2024-09-25 | 2024-09-25 | View Filing |
| UPLOAD | 2024-09-23 | 2024-09-23 | View Filing |
| CORRESP | 2024-09-23 | 2024-09-23 | View Filing |
| CORRESP | 2024-09-23 | 2024-09-23 | View Filing |
Algorithm Performance
Upgrade To Premium for Full Access
| Algorithm | Profit/Loss | Profit Factor | # Trades | Sharpe | Sortino | Efficiency |
|---|---|---|---|---|---|---|
| Elliott Wave Strategy | 114.08% | 2 | 3 | 0.03 | 0.11 | 61.22 |
| Neural Forcast | 98.87% | 1 | 792 | 0.04 | 0.1 | 46.02 |
| Williams PercentR Strategy | 92.04% | 0.99 | 405 | 0.06 | 0.18 | 39.19 |
| xxxxxxxxx | xxxxxxx% | x | xxx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xxx | xxxx | xxx | xxxx |
| xxxxxxxxxx | xxxxxxx% | xxxx | xxx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xxx | xxxx | xxxx | x |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xxx | xxxx | xxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xxx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xxx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xxx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xxx | xxxx | xxxx | x |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xxx | xxxx | xxxx | xxx |
| xxxxxxxxxxxxx | xxxxxxx% | xxxx | x | xxxx | xxxx | xxxx |
| xxx | xxxxxxx% | xxxx | xxx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xxx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxx | xxxxx |
| xxxxxxxxxx | xxxxxxx% | x | xxx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xxx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xxx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xxx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxx% | x | xxx | xxxx | xxxx | xxxxx |
| xxxxxxxxx | xxxxxxx% | x | xxx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xxx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xxx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxx | xxxxxxx% | xxx | xx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xxx | x | xxxx | xxxxx |
| xxxx | xxxxxx% | x | xxx | x | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | x | xxxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxx% | x | xxx | x | xxxx | xxxxx |
| xxxx | xxxxxxx% | x | xxx | xxxxx | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | x | xxxxx |
| xxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxxx |